Lab animals given N-acetylglucosamine have seen disease activity halted and in a few cases mild improvement in a study of the dietary supplement’s effects on the lab equivalent for multiple sclerosis.
International researchers employing a large subject base have discovered
29 genetic variants to add to the 23 previously identified as playing a role in the immune system leading to nerve damage in multiple sclerosis.
Small dose dextromethorphan administered to mice having the laboratory model of multiple sclerosis experienced reduced loss of myelin and fewer paralytic effects. Dextromethorphan is a safe chemical ingredient found in over the counter cough medicine.
Macaque monkeys at a primate research center have spontaneously developed a disease with similar characteristics of multiple sclerosis in humans. It is hoped that further research among this population of affected primates will provide answers and treatment for the disease.
Researchers in the UK have found a compound that not only inhibits the inflammation occurring in MS it also stimulates natural production of interferon-beta. Various interferon are now injected by MS patients to delay progression of the disease. This discovery is being investigated as a safer, more efficient way of accomplishing that task.
Mylan Inc. gets the door open a little further in their quest to market a generic form of the multiple sclerosis treatment Copaxone after a summary judgement filed by the manufacturer Teva Pharmaceuticals was denied.
Great Britain’s NHS is denying a potential pain and spasticity relieving preparation to multiple sclerosis patients despite the fact that it is a licensed medication that very well might provide relief when other drugs fail to do so.
Researchers at the University of California, San Diego School of Medicine have discovered a steroid hormone that plays a role in controlling inflammation in the brain, may provide an explanation why more women are afflicted with MS, and might provide an avenue of treatment for MS and other neurological conditions.
CCSVI Study Makes Cloudy Connection
A Canadian study which combined and parsed data from eight different trials concerning treatment for CCSVI in individuals having MS has shown a possible link. Click on link for a google search page highlighting various press accounts reporting on the study.